• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background

    Inhalation Anesthesia Companies

    ID: MRFR/HC/6587-HCR
    200 Pages
    Rahul Gotadki
    October 2025

    Inhalation anesthesia is a medical technique that involves administering anesthetic agents through inhalation to induce and maintain a state of controlled sedation or unconsciousness during surgical procedures. Several companies specialize in the development and manufacturing of inhalation anesthesia products, including inhalation anesthetics and related equipment.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Inhalation Anesthesia Market Research Report-Forecast to 2035 Infographic
    Summary Table of Contents Segmentation Download PDF

    Top Industry Leaders in the Inhalation Anesthesia Market

    Inhalation Anesthesia Key CompaniesLatest Inhalation Anesthesia Companies Update



    • Oct 2023: Hikma MENA FZE, a division of Hikma Pharmaceuticals, and CanariaBio have reached a distribution and licensing agreement for oregovomab, a treatment for advanced ovarian cancer. Oregovomab will be supplied throughout the Middle East and North Africa (MENA) region by Hikma MENA FZE. A murine monoclonal antibody called oregovomab targets the tumor-associated antigen CA125, which triggers a cytotoxic immune response from the host against tumor cells that display the CA 125 biomarker. Combining oregovomab with first-line chemotherapy resulted in a significantly longer progression-free survival of 41.8 months, compared to 12.2 months with standard chemotherapy, according to a randomized Phase II research. In the Phase III FLORA-5 trial, oregovomab is also being studied in patients with advanced ovarian cancer in addition to carboplatin and paclitaxel. The European Medicines Agency and the US Food and Drug Administration designated it as an orphan medicine.



    • The introduction of +RFID smart labels for Diprivan (Propofol) injectable emulsion, USP, 200 mg per 20 ml in single-dose vials, has been announced by Fresenius Kabi for the US market. All "major" radio-frequency identification (RFID) kits and tray systems in the nation are compatible with these smart labels. By doing away with the need for manual medication tagging, our RFID label technology improves the efficiency and safety of the medication management process while also saving time. Diprivan +RFID has been certified by Auburn University's ARC RFID laboratory and examined by The Axia Institute of Michigan State University in addition to Fresenius' testing to guarantee that it satisfies national performance and quality criteria.


    List of Inhalation Anesthesia Key companies in the market

    • Baxter International Inc.

    • Halocarbon Products Corporation

    • Hikima Pharmaceuticals plc.

    • Lunan Pharmaceutical Group Co. Ltd

    • Piramal Enterprises Limited

    • Jiangsu Hengrui Medicine Co. Ltd

    • Fresenius Kabi AG

    • AbbVie Inc.